피임기구 시장 보고서 : 제품 유형별, 최종사용자별, 유통 채널별, 지역별(2026-2034년)

The global contraceptive devices market size reached USD 15.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 24.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.71% during 2026-2034. The increasing awareness about the importance of family planning, the growing incidence of unintended pregnancies, and the rising government initiatives and funding to promote family planning programs represent some of the key factors driving the market.

Contraceptive devices are essential tools that help individuals and couples prevent unintended pregnancies. These devices effectively prevent pregnancy by inhibiting the fertilization process. They are made using various materials and technologies, depending on the type of device. Barrier methods, such as condoms and diaphragms, prevent sperm from reaching the egg and are typically made of latex, polyurethane (PU), or other materials. Hormonal contraceptives, such as birth control pills, injections, and patches contain synthetic hormones that regulate the woman's menstrual cycle and prevent ovulation. On the other hand, intrauterine devices (IUDs) are made of either copper or plastic and are inserted into the uterus to prevent pregnancy. Contraceptive devices offer numerous advantages, such as providing individuals with the autonomy to plan their families and make informed choices about their reproductive health. They can be used by both men and women, offering a wide range of options for contraception. They are generally safe and effective when used correctly, and many devices also provide additional benefits, such as protection against sexually transmitted infections (STIs) or reduced menstrual bleeding.

CONTRACEPTIVE DEVICES MARKET TRENDS:

The global contraceptive devices market is driven by several factors, including the increasing awareness and adoption of family planning methods and the growing incidence of unintended pregnancies. Moreover, the rising government initiatives and funding to promote family planning programs and the surging prevalence of STIs are boosting the market growth. Furthermore, the availability of various contraceptive devices, including oral contraceptives, intrauterine devices, condoms, and subdermal implants, and inflating consumer expenditure power are driving the market growth. Apart from this, the development of long-acting reversible contraceptives, the expansion of the e-commerce sector, and the inflating trend of product innovations are fueling the market growth. In line with this, the increasing demand for non-hormonal and natural contraceptives and the surging acceptance of female-controlled contraceptive methods are also contributing to the market growth. Other factors, such as the growing number of partnerships and collaborations between manufacturers and healthcare providers, as well as the expansion of distribution networks in emerging markets, are expected to propel the market growth further.

KEY MARKET SEGMENTATION:

Device Type Insights:

• Condoms
• Diaphragms
• Cervical Caps
• Sponges
• Vaginal Rings
• IUDs
• Others

End User Insights:

• Male
• Female

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for contraceptive devices. Some of the factors driving the North America contraceptive devices market included increasing awareness and acceptance, technological advancements, government initiatives, and rising prevalence of STIs.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global contraceptive devices market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Allergan plc, Bayer AG, Church & Dwight Co., Inc., CooperSurgical Inc., Merck & Co., Mylan Inc., Pfizer Inc., Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., and The Female Health Company. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

1. How big is the global contraceptive devices market?

2. What is the expected growth rate of the global contraceptive devices market during 2026-2034?

3. What are the key factors driving the global contraceptive devices market?

4. What has been the impact of COVID-19 on the global contraceptive devices market?

5. What is the breakup of the global contraceptive devices market based on the device type?

6. What is the breakup of the global contraceptive devices market based on the end user?

7. What is the breakup of the global contraceptive devices market based on the distribution channel?

8. What are the key regions in the global contraceptive devices market?

9. Who are the key players/companies in the global contraceptive devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Contraceptive Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Device Type

• 6.1 Condoms
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Diaphragms
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Cervical Caps
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Sponges
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Vaginal Rings
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 IUDs
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by End User

• 7.1 Male
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Female
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Stores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Allergan Plc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Bayer AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Church & Dwight Co. Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 CooperSurgical Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Merck & Co.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Mylan Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Pfizer Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Reckitt Benckiser Group plc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Teva Pharmaceutical Industries Ltd.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 The Female Health Company
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis